Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, 28 Day, Three-arm, Parallel Group Study of A0001 in the Treatment of Subjects With Friedreich's Ataxia

NCT01035671 is registered in ClinicalTrials.gov with Penwest Pharmaceuticals Co. as lead sponsor.

NCT NCT01035671
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01035671 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, 28 Day, Three-arm, Parallel Group Study of A0001 in the Treatment of Subjects With Friedreich's Ataxia
Lead sponsor
Penwest Pharmaceuticals Co.
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2009
Completion date
March 31, 2011
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

friedreich's ataxia